Sarepta and stridebio announce multi-target strategic collaboration to advance novel gene therapies

Sarepta and stridebio announce multi-target strategic collaboration to advance novel gene therapies.sarepta therapeutics inc - sarepta granted an exclusive option for four additional neuromuscular and cns targets.sarepta therapeutics inc - sarepta granted an exclusive license to four cns targets.sarepta therapeutics inc - stridebio will receive a $48 million upfront payment in form of cash and sarepta stock.sarepta therapeutics inc - sarepta has made a commitment to invest in stridebio's next financing round..sarepta therapeutics inc - stridebio may also get significant future development, regulatory and commercial milestones for four programs.sarepta - can expand collaboration to include up to additional 4 targets with upfront payment of up to $42.5 million with future milestone payments.
SRPT Ratings Summary
SRPT Quant Ranking